Compare Medpace Holdings Inc (MEDP) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs NetFlix Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while NetFlix Inc trades at $70.34 (market cap $298.01B). The key difference: NetFlix Inc is far larger — about 17.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and NetFlix Inc for 125 Days on average.
| MEDP | NFLX | |
|---|---|---|
Market Cap | $16.82B | $298.01B |
Volume | 223,093 | 45,805,108 |
Sector | Health | Media |
52-Week High | $630.19 | $124.13 |
52-Week Low | $393.42 | $67.06 |
Typical Hold Time | 14 Days | 125 Days |
Enterprise Value | $16.44B | $303.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Netflix trades at $69.70, up 1.47% today, with strong fundamentals including 28.2% net margin and 49.5% ROE. The stock shows bearish technical signals despite beating earnings expectations for three consecutive quarters. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 29% upside potential.
Netflix presents a compelling growth story with expanding profitability and strategic content investments, though technical weakness and competitive pressures warrant caution. The company's strong cash flow generation and institutional interest support long-term upside, but investors should monitor execution risks in the evolving streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
